5 Stocks Insiders Love Right Now
A pharmaceutical and diagnostics player whose insiders are doing some active buying is Opko Health (OPK), which is focused on developing a range of solutions, including molecular diagnostics tests, pharmaceuticals and vaccines. This stock has done absolutely nothing so far in 2012, with shares virtually flat on the year.
Opko Health has a market cap of $1.39 billion and an enterprise value of $1.33 billion. This stock trades at a lofty valuation, with a price-to-sales of 32.71 and a price-to-book of 13.65. This is a cash-rich company, since the total cash position on its balance sheet is $87.42 million and its total debt is $12.55 million.The CEO and chairman of the board just bought 500,000 shares, or about $2.36 million worth of stock, at $4.72 per share. From a technical perspective, OPK is currently trading above its 200-day moving average and right below its 50-day moving average, which is neutral trendwise. For the past month and change, this stock has found some buying support at around $4.70 to $4.66 a share, and it has run into selling resistance near $5.50 and above. If you're a bullish on OPK, then I would look for long-biased trades once this stock takes out its 50-day moving average of $5.03 with high volume. Look for volume on that move that's near or well above its three-month average action of 1,414,680 shares. If we get that action soon, I would then only add to any long positions once $5.60 to $5.85 a share are taken out with big volume. Otherwise, I would simply lock in profits near those levels if the sellers continue to defend their positions. Opko shows up in Jana Partners' portfolio as of the most recently reported period, with a 2 million-share position. Follow @stockpickr
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV